H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Zura Bio with a Neutral rating and $5 price target. Zura is a clinical stage biotechnology company developing autoimmune disease therapeutics, the analyst tells investors in a research note. The firm says the data for lead asset tibulizumab appears mixed, with Phase 1 PK data not as clear as positive preclinical data.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA: